

**ERZOFRI - (39MG/0.25ML, 78MG/0.5ML, 117MG/0.75ML, 156MG/1ML, 234MG/1.5ML, 351MG/2.25ML ;  
SUSPENSION,EXTENDED RELEASE)**

<b>Generic Name</b>	PALIPERIDONE PALMITATE	<b>Innovator</b>	Luye pharma
<b>Dosage</b>	39MG/0.25ML, 78MG/0.5ML, 117MG/0.75ML, 156MG/1ML, 234MG/1.5ML, 351MG/2.25ML ; SUSPENSION,EXTENDED RELEASE	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	None		
<b>Complexities</b>	No		

**Chronology Of Events**

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

**Executive Summary**

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

**Patent Status**

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

**Launch Timelines and Competition**

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

**Chronology Of Events**

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.